Open label, uncontrolled, study of XRP9881 (Larotaxel) in combination with weekly trastuzumab (Herceptin) in patients with HER2 positive metastatic breast cancer (MBC)

Trial Profile

Open label, uncontrolled, study of XRP9881 (Larotaxel) in combination with weekly trastuzumab (Herceptin) in patients with HER2 positive metastatic breast cancer (MBC)

Completed
Phase of Trial: Phase II

Latest Information Update: 09 May 2016

At a glance

  • Drugs Larotaxel (Primary) ; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 07 Jul 2009 Actual end date (1 Mar 2008) and actual patient number (6) added as reported by ClinicalTrials.gov.
    • 26 Apr 2008 The expected completion date for this trial is now 1 May 2008.
    • 14 Feb 2008 Status changed from recruiting to in progress, in accordance with clinicaltrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top